Lung Cancer
From the Journals
Capmatinib plus gefitinib overcomes EGFR resistance in NSCLC
In patients with a high level of MET amplification, responses were more common, with almost half of the NSCLC patients responding.
From the Journals
Adding checkpoint inhibitors to radiotherapy requires particular caution in this one scenario
Among scenarios where immune checkpoint inhibitors (ICIs) might be combined, particular caution is needed in the setting of brain metastases,...
From the Journals
More frequent CT surveillance in NSCLC doesn’t improve survival
A study looks at the impact of surveillance frequency on NSCLC survival.
From the Journals
Baseline steroids may reduce efficacy of checkpoint inhibitors
Corticosteroid use at the time of PD-1/PD-L1 blockade was linked with decreased PFS and OS in multivariate analysis.
News
FDA grants full approval to pembrolizumab for advanced NSCLC
The checkpoint inhibitor is approved with pemetrexed and platinum chemotherapy for first-line treatment of metastatic nonsquamous NSCLC, with no...
News
FDA grants accelerated approval for Opdivo in metastatic SCLC
The checkpoint inhibitor is approved for patients with advanced SCLC whose cancer has progressed after platinum-based chemotherapy and at least...
From the Journals
Aggressive drainage regimen may promote spontaneous pleurodesis
The optimal regimen of drainage after an indwelling pleural catheter is placed is a subject of debate.
From the Journals
Low-dose CT fails to improve small cell lung cancer survival
Previous studies on the value and impact of low-dose CT for SCLC diagnosis have been divergent.
From the Journals
Broad genomic testing of NSCLC in community oncology disappoints
Among patients with advanced NSCLC treated in community oncology practices, broad-based genomic sequencing seldom exclusively informed the...
From the Journals
EGFR-mutant NSCLC may still respond to PD-1 blockade
A woman presenting with EGFR-mutant non–small-cell lung cancer has shown high PD-L1 expression and responded well to PD-1 inhibitors.
From the Journals
Score predicts 3-month mortality in malignant pleural effusion
A combination of biomarkers and clinical markers could be used to predict 3-month mortality and treatment response in malignant pleural effusion...